摘要
目的:了解氯沙坦和依那普利治疗原发性高血压的有效性和不良反应的差异。方法:应用Meta分析对19篇文献中两药治疗原发性高血压的有效性和安全性,进行同质性检验和合并效应量的估计。结果:①同质性检验:有效性,x2=10．186,自由度18;安全性,x2=12．207,自由度18,两者P均>0．05。②合并效应量的估计:有效性,OR合并=1．180,OR合并95％可信区间为0．921～1．511。OR合并的检验:x2=1．706,P>0．05;安全性,OR合并= 0．250,OR合并95％的可信区间为0．186～0．337,OR合并的检验:x2=83．85,P<0．01。结论:氯沙坦、依那普利降血压疗效相似,氯沙坦不良反应明显低于依那普利。
Objective： To evaluate the differences in therapeutic effects and safety of losartan and enalapril. Method： The efficacy and safety of losartan or enalapril in treating hypertension were comprehensively evaluated with the meta-analysis in homogeneity tests and combined tests in 19 studies. Result： The homogeneity test showed that the cited studies of the efficacy and safety were homogeneous with χ^2 = 10. 186,χ^2 = 12. 207, P 〉0.05. In the combined tests, the value of efficacy was OR merging = 1. 180 and OR merging 95%. The confidence interval was 0.921 - 1.511, and OR merging test ： χ^2 = 1. 706, P 〉 0.05. The value of safety was OR emerging =0.250, OR merging 95%. The confidence interval was 0. 186 -0. 337,OR merging test ： χ^2 = 83.85, P 〈 0.01. Conclusion： There was no significant difference in the efficacy of losartan and enalapril, but losartan is safer and has fewer adverse effects than enalapril.
出处
《药物流行病学杂志》
CAS
2007年第1期19-22,共4页
Chinese Journal of Pharmacoepidemiology
